Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 7/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.45 |
| ▸ | KIT | P10721 | 2/20 | 0.44 |
| ▸ | SGK1 | O00141 | 4/20 | 0.42 |
| ▸ | PI4KA | P42356 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25035356 | 0.89 | ERN1 (0.49) | ERN1PIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL25035568 | 0.88 | ERN1 (0.45) | ERN1PIK3CGKITPI4KA | |
| SCHEMBL25035544 | 0.85 | MTOR (0.42) | PIK3CGPIK3CDPIK3CAPIK3CBSGK1 | |
| SCHEMBL29356052 | 0.85 | ERN1 (0.52) | ERN1 | |
| SCHEMBL22190906 | 0.85 | ERN1 (0.52) | ERN1 | |
| SCHEMBL22190907 | 0.85 | ERN1 (0.52) | ERN1 | |
| SCHEMBL25035486 | 0.84 | ERN1 (0.43) | ERN1PIK3CGPIK3CAKITPI4KA | |
| SCHEMBL25035485 | 0.83 | ERN1 (0.48) | ERN1PIK3CGKITPI4KA | |
| SCHEMBL25035369 | 0.83 | ERN1 (0.57) | ERN1 | |
| SCHEMBL22200350 | 0.83 | USP2 (0.38) | ERN1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | PARAZA PHARMA, INC. (CA) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | TYMP, TYMS, DPYD | ERN1 3167/4885PIK3CG 971/4885PIK3CD 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.